Defining asthma control
How do patient perceptions of asthma control differ from guideline definitions?
This browser is no longer supported.
To provide you with the best possible experience, we kindly ask you to switch to a supported browser:
Anoro Ellipta 20 mcg
has been added to your basket
25% more patients experience an improvement in their asthma control with Relvar vs other commonly used ICS/LABAs*1
The Salford Lung Study (SLS) was a robust, open-label, pragmatic RCT comparing Relvar with usual care (ICS or ICS/LABA) in 4233 patients.1
At baseline, the most commonly prescribed ICS/LABAs were:2
This graph has been independently created by GSK from the original data. The same results were first published in Woodcock A, et al. Lancet 2017;390:2247–2255.
Looking at the individual aspects of the Asthma Control Test (ACT), Relvar treatment provides a higher mean change in symptom improvement from baseline vs other commonly prescribed ICS/LABAs.‡4
From educational videos to podcasts, Breathing Space is a GSK initiative designed to share the latest thinking on lung health and provide a space for pulmonologists and other respiratory specialists to gather insights and explore best practice.